[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Contact ::
Main Menu
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Last site contents
:: Editorial Board
:: About Iranian Journal of Endocrinology and Metabolism
:: Volume 22, Issue 1 (10-2020) ::
2020, 22(1): 30-40 Back to browse issues page
The measurement technologies of thyrotropin receptor antibodies from the past to the present
Safura Pakizehkar , Samaneh Hosseinzadeh , Mehdi Hedayati
Cellular and Molecular Endocrine Research Center (CMERC), Research Institute for Endocrine Sciences of Shahid Beheshti University of Medical Sciences, Tehran, Iran , hedayati47@gmail.com ایمیل
Abstract:   (2861 Views)
Thyroid Stimulating Hormone Receptor (TSH-R) autoantibodies are the main cause of Graves' disease and its external thyroid manifestations such as ophtalmopathy and dermatopathy. These antibodies are functionally different and are commonly called TSH receptor antibodies (TRAbs). In fact, TRAbs are a set of autoantibodies including TSHR-stimulating antibodies (TSAbs), TSHR- blocking antibodies (TBAbs), and neutral antibodies. The measurement of TRAbs is clinically important and various commercial tests with high sensitivity and specificity are available for diagnostic purposes. If the diagnostic purpose of the TRAbs assay is the non-functional evaluation of autoantibodies, competitive binding immunoassays are used.  These methods are based on the ability of TRAbs in patient’s sample to compete and prevent ligand binding (TSH or anti-TSHR monoclonal antibodies) to the receptor. TSAbs and TBAbs appear to have common overlapping epitopes of the TSH-binding site which hinders them to be differentiated by competitive TRAbs assays. On the other hand, if the diagnostic purpose is to evaluate antibody function and differentiate between TSAbs and TBAbs, cell-based bioassays are used. The basis of these methods are the use of living cells to evaluate the function of autoantibodies and distinguish TSAbs and TBAbs based on the increase and decrease of the intracellular Cyclic adenosine monophosphate (cAMP). Since TSAbs and TBAbs have different pathogenic roles with different clinical symptoms and require different treatment protocols, differential diagnosis of TSAbs and TBAbs is of great clinical importance. In this review, different generations of competitive binding immunoassays and cell-based bioassays in the order of evolution, have been discussed.
Keywords: TSH receptor antibodies, Autoantibodies, Thyroid, Autoimmune disease, Graves’ disease
Full-Text [PDF 2181 kb]   (1126 Downloads)    
Type of Study: Review | Subject: Biochemistry
Received: 2020/04/2 | Accepted: 2020/08/3 | Published: 2020/10/1
Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Pakizehkar S, Hosseinzadeh S, Hedayati M. The measurement technologies of thyrotropin receptor antibodies from the past to the present. Iranian Journal of Endocrinology and Metabolism 2020; 22 (1) :30-40
URL: http://ijem.sbmu.ac.ir/article-1-2713-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 22, Issue 1 (10-2020) Back to browse issues page
مجله ی غدد درون‌ریز و متابولیسم ایران، دو ماهنامه  پژوهشی مرکز تحقیقات غدد درون‌ریز و متابولیسم، Iranian Journal of Endocrinology and Metabolism
Persian site map - English site map - Created in 0.06 seconds with 38 queries by YEKTAWEB 4652